Donald Lehr Sells 29,131 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) insider Donald Lehr sold 29,131 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $127,011.16. Following the sale, the insider directly owned 755,461 shares of the company’s stock, valued at $3,293,809.96. This represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Stock Down 5.1%

PGEN traded down $0.22 during midday trading on Monday, reaching $4.12. 4,830,773 shares of the company were exchanged, compared to its average volume of 4,257,618. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The company’s fifty day moving average price is $4.02 and its 200 day moving average price is $4.09. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -3.49 and a beta of 1.06. Precigen, Inc. has a one year low of $1.28 and a one year high of $5.47.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%. As a group, analysts expect that Precigen, Inc. will post 0.04 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on PGEN. HC Wainwright upped their target price on Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a report on Sunday. Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, Citizens Jmp upped their target price on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.50.

Institutional Investors Weigh In On Precigen

Several institutional investors have recently made changes to their positions in PGEN. State Street Corp lifted its position in shares of Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after acquiring an additional 6,335,033 shares in the last quarter. SymBiosis Capital Partners LLC purchased a new stake in shares of Precigen during the fourth quarter worth $12,540,000. Bank of America Corp DE lifted its position in shares of Precigen by 201.1% during the third quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after acquiring an additional 1,673,731 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Precigen by 196.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock worth $9,087,000 after acquiring an additional 1,440,446 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in shares of Precigen during the third quarter worth $2,796,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.